<?xml version='1.0' encoding='utf-8'?>
<document id="12796358"><sentence text="Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase."><entity charOffset="18-35" id="DDI-PubMed.12796358.s1.e0" text="imatinib mesylate" /></sentence><sentence text="The purpose is to describe the Food and Drug Administration (FDA) review and approval of imatinib (Gleevec; Novartis Pharmaceuticals, East Hanover, NJ) for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in chronic phase"><entity charOffset="89-97" id="DDI-PubMed.12796358.s2.e0" text="imatinib" /></sentence><sentence text="" /><sentence text="The FDA reviewed data in electronic format from a randomized controlled clinical trial of 1106 adult patients with newly diagnosed Philadelphia chromosome-positive CML in chronic phase, comparing imatinib with the combination of IFN-alpha and cytarabine"><entity charOffset="196-204" id="DDI-PubMed.12796358.s4.e0" text="imatinib" /><entity charOffset="229-238" id="DDI-PubMed.12796358.s4.e1" text="IFN-alpha" /><entity charOffset="243-253" id="DDI-PubMed.12796358.s4.e2" text="cytarabine" /><pair ddi="false" e1="DDI-PubMed.12796358.s4.e0" e2="DDI-PubMed.12796358.s4.e0" /><pair ddi="false" e1="DDI-PubMed.12796358.s4.e0" e2="DDI-PubMed.12796358.s4.e1" /><pair ddi="false" e1="DDI-PubMed.12796358.s4.e0" e2="DDI-PubMed.12796358.s4.e2" /><pair ddi="false" e1="DDI-PubMed.12796358.s4.e1" e2="DDI-PubMed.12796358.s4.e1" /><pair ddi="false" e1="DDI-PubMed.12796358.s4.e1" e2="DDI-PubMed.12796358.s4.e2" /></sentence><sentence text="" /><sentence text="Imatinib showed clinically and statistically significantly better results for time-to-progression to accelerated phase or blast crisis, progression-free survival, complete hematological response rate, and cytogenetic response rate"><entity charOffset="0-8" id="DDI-PubMed.12796358.s6.e0" text="Imatinib" /></sentence><sentence text=" With a median follow-up of 14 months, a maximum follow-up of 19" /><sentence text="5 months, and an expected median survival of 5-6 years on the IFN-alpha/cytarabine control arm, few of the expected progressions to accelerated or blast phase or deaths have occurred" /><sentence text=" Imatinib was also better tolerated"><entity charOffset="1-9" id="DDI-PubMed.12796358.s9.e0" text="Imatinib" /></sentence><sentence text=" Edema, nausea, rigors, neutropenia, and headache were more frequent in women" /><sentence text=" Only 57% of the IFN-alpha target dose was administered, and only 68% of patients received any cytarabine"><entity charOffset="95-105" id="DDI-PubMed.12796358.s11.e0" text="cytarabine" /></sentence><sentence text=" However, this does not appear to adequately explain the superiority of imatinib observed in this trial"><entity charOffset="72-80" id="DDI-PubMed.12796358.s12.e0" text="imatinib" /></sentence><sentence text=" Results of a population pharmacokinetic study in a subgroup of 371 patients and a separate rifampin-imatinib drug-drug interaction study in healthy volunteers are presented"><entity charOffset="92-100" id="DDI-PubMed.12796358.s13.e0" text="rifampin" /></sentence><sentence text="" /><sentence text="On December 20, 2002, imatinib was granted accelerated approval under subpart H, rather than regular approval"><entity charOffset="22-30" id="DDI-PubMed.12796358.s15.e0" text="imatinib" /><entity charOffset="78-79" id="DDI-PubMed.12796358.s15.e1" text="H" /><pair ddi="false" e1="DDI-PubMed.12796358.s15.e0" e2="DDI-PubMed.12796358.s15.e0" /><pair ddi="false" e1="DDI-PubMed.12796358.s15.e0" e2="DDI-PubMed.12796358.s15.e1" /></sentence><sentence text=" Follow-up is short compared with the natural history of chronic phase CML or more mature results with established therapies such as IFN-alpha or transplantation" /><sentence text=" If imatinib should stop working after 1"><entity charOffset="4-12" id="DDI-PubMed.12796358.s17.e0" text="imatinib" /></sentence><sentence text="5-2 years, the results could be importantly different from the present analysis" /><sentence text=" As a Phase IV postmarketing commitment, the applicant has agreed to provide follow-up reports on this imatinib study annually for the next 6 years"><entity charOffset="103-111" id="DDI-PubMed.12796358.s19.e0" text="imatinib" /></sentence><sentence text="" /></document>